Fibrous cap thickness

1 paper1 finding

Animals1

Interventions

1

Navitoclax

downin mice1−60%

1 study

Navitoclax decreases fibrous cap thickness in mice (-60%).
“ABT-263 treatment also reduced α-SMA+ fibrous cap thickness by 60% and was associated with a > 50% mortality rate.”
Animalsin western diet-fed Apoe-/- mice with advanced atherosclerosis100 mg/kg/bw or 50 mg/kg/bw6 weeks or 9 weeks
Treatment of advanced atherosclerotic mice with ABT-263 reduced indices of plaque stability and increased mortality
JCI insight23 Jan 2024

More on Navitoclax

Latest

5 in 12 months

Circulation8 Sep

Impaired Glycolysis Leads to Defective Efferocytosis and Impaired Plaque Resolution in Tet2 Clonal Hematopoiesis

Experiments in miceGlycolysis

Frontiers in Physiology6 Aug

Genetic ablation of TRPC6 facilitated age-dependent atherosclerosis progression in an ApoE-/- mouse model

Experiments in miceAPOE

Chinese Journal of Integrative Medicine27 Apr

Berberine Ameliorates Atherosclerosis by Promoting Mitochondrial Biogenesis via SIRT1/PGC-1α Signaling Pathway

Experiments in miceBerberine

Redox Biology27 Nov

Melatonin attenuates atherosclerotic plaque vulnerability through SIRT6-dependent regulation of vascular smooth muscle cells senescence

Experiments in miceMelatonin

AHA Scientific Sessions 2025 Abstract3 Nov

The Senolytic Navitoclax (ABT263) Reduces Coronary Atherosclerosis and Upregulates Plaque Stability in Atherosclerotic Pigs

Experiments in pigsSenolytics

JCI Insight23 Jan

Treatment of advanced atherosclerotic mice with ABT-263 reduced indices of plaque stability and increased mortality

Experiments in miceAtherosclerosis

bioRxiv28 Jul

Treatment of advanced atherosclerotic mice with the senolytic agent ABT-263 is associated with reduced indices of plaque stability and increased mortality

Preprint: experiments in animalsInterventions